Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

Zhang, Zhenfeng, Lee, Jae Cheol, Lin, Luping, Olivas, Victor, Au, Valerie, LaFramboise, Thomas, Abdel-Rahman, Mohamed, Wang, Xiaoqi, Levine, Alan D, Rho, Jin Kyung, Choi, Yun Jung, Choi, Chang-Min, Kim, Sang-We, Jang, Se Jin, Park, Young Soo, Kim, Woo Sung, Lee, Dae Ho, Lee, Jung-Shin, Miller, Vincent A, Arcila, Maria, Ladanyi, Marc, Moonsamy, Philicia, Sawyers, Charles, Boggon, Titus J, Ma, Patrick C, Costa, Carlota, Taron, Miquel, Rosell, Rafael, Halmos, Balazs, Bivona, Trever G·2012·Nature Genetics
DOI 10.1038/ng.2330

Cited by (1,000)

Items 601–700 of 1,000

  1. First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer
    Xingsheng Hu, Xin Zheng, Sheng Yang, Lin Wang, Xuezhi Hao, Xinge Cui, Lieming Ding, Li Mao, Pei Hu, Yuankai Shi · 2020 · Journal of Hematology & Oncology
  2. Bimodal regulation of the PRC2 complex by USP7 underlies tumorigenesis
    Dongxue Su, Wenjuan Wang, Yongqiang Hou, Liyong Wang, Xianfu Yi, Cheng Cao, Yuejiao Wang, Huan Fang Gao, Yue Wang, Chao Yang et al. · 2021 · Nucleic Acids Research
  3. Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers
    Jill Kolesar, Keng Hee Peh, Levin Thomas, Gayathri Baburaj, Nayonika Mukherjee, Raveena Kantamneni, Shirley Christabel Lewis, Ananth Pai, Karthik Udupa, Naveena A. N. Kumar et al. · 2022 · Molecular Cancer
  4. The Selective Intravenous Inhibitor of the MET Tyrosine Kinase SAR125844 Inhibits Tumor Growth in MET -Amplified Cancer
    Coumaran Égile, Mireille Kenigsberg, Christine Delaisi, Françoise Bégassat, Véronique Do-Vale, Jessica Mestadier, Fabrice Bonche, Tsiala Bénard, Jean‐Paul Nicolas, Sandrine Valence et al. · 2014 · Molecular Cancer Therapeutics
  5. Multi-omics analysis reveals that ornithine decarboxylase contributes to erlotinib resistance in pancreatic cancer cells
    Won‐Jun Jang, Boyeon Choi, Sang-Hoon Song, Naeun Lee, Dong Joon Kim, Sooyeun Lee, Chul‐Ho Jeong · 2017 · Oncotarget
  6. Design, synthesis and biological evaluation of new Axl kinase inhibitors containing 1,3,4-oxadiazole acetamide moiety as novel linker
    Congjun Xu, Yufei Han, Sicong Xu, Ruxin Wang, Ming Yue, Yu Tian, Xiaofan Li, Yanfang Zhao, Ping Gong · 2019 · European Journal of Medicinal Chemistry
  7. Resistance of Lung Cancer to EGFR-Specific Kinase Inhibitors: Activation of Bypass Pathways and Endogenous Mutators
    Ilaria Marrocco, Yosef Yarden · 2023 · Cancers
  8. The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy
    Xinlin Liu, Junwen Deng, Renshuai Zhang, Jiyao Xing, Yudong Wu, Wujun Chen, Bing Liang, Dongming Xing, Jiazhen Xu, Miao Zhang · 2023 · Frontiers in Immunology
  9. Histologic transformation of non‐small‐cell lung cancer in response to tyrosine kinase inhibitors: Current knowledge of genetic changes and molecular mechanisms
    Aya Shiba‐Ishii, Noriko Takemura, Hitomi Kawai, Daisuke Matsubara · 2024 · Cancer Science
  10. The novel phosphoinositide 3‐kinase–mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor
    Takako Sano, Shinji Takeuchi, Takayuki Nakagawa, Daisuke Ishikawa, Shigeki Nanjo, Tadaaki Yamada, Takahiro Nakamura, Kunio Matsumoto, Seiji Yano · 2013 · International Journal of Cancer
  11. Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells
    Kinga Pénzes, Christine Baumann, István Szabadkai, László Őrfi, Gÿorgý Kéri, Axel Ullrich, Robert Torka · 2014 · Cancer Biology & Therapy
  12. Fisetin, a dietary phytochemical, overcomes Erlotinib-resistance of lung adenocarcinoma cells through inhibition of MAPK and AKT pathways.
    Liang Zhang, Yi Huang, Wenlei Zhuo, Yi Zhun Zhu, Bo Zhu, Zhengtang Chen · 2016 · PubMed Central
  13. AXL is a marker for epithelial‑mesenchymal transition in esophageal squamous cell carcinoma
    Guoan Zhang, Xia Kong, Meng Wang, Hongli Zhao, Sha Han, Ronghang Hu, Jian An Huang, Wen Cui · 2017 · Oncology Letters
  14. Synthesis, and anti-proliferative, Pim-1 kinase inhibitors and molecular docking of thiophenes derived from estrone
    Rafat M. Mohareb, Eman M. Samir, Peter A. Halim · 2018 · Bioorganic Chemistry
  15. Blockade of AXL activation overcomes acquired resistance to EGFR tyrosine kinase inhibition in non-small cell lung cancer
    Feng Wang, Xuewen Liu, Boris Bartholdy, Haiying Cheng, Balázs Halmos · 2019 · Translational Cancer Research
  16. Repositioning Aspirin to Treat Lung and Breast Cancers and Overcome Acquired Resistance to Targeted Therapy
    Ling Li, Mengdi Hu, Tao Wang, Hongzhuan Chen, Lu Xu · 2020 · Frontiers in Oncology
  17. The potential role of YAP in Axl-mediated resistance to EGFR tyrosine kinase inhibitors.
    Sarah Saab, Olin Shih-Shin Chang, Kentaro Nagaoka, Mien‐Chie Hung, Hirohito Yamaguchi · 2019 · PubMed Central
  18. LncRNA MIR17HG inhibits non-small cell lung cancer by upregulating miR-142-3p to downregulate Bach-1
    Sen Wei, Jinghao Liu, Xin Li, Xingyu Liu · 2020 · BMC Pulmonary Medicine
  19. MERTK Inhibition: Potential as a Treatment Strategy in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer
    Chao‐Ju Chen, Yu‐Peng Liu · 2021 · Pharmaceuticals
  20. Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer
    Célia Delahaye, Sarah Figarol, Anne Pradines, Gilles Favre, Julien Mazières, Olivier Calvayrac · 2022 · Cancers
  21. c-MET kinase inhibitors: a patent review (2011 – 2013)
    Kongkai Zhu, Xiangqian Kong, Dan Zhao, Zhongjie T. Liang, Cheng Luo · 2013 · Expert Opinion on Therapeutic Patents
  22. Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming
    Praveena Shree Thiagarajan, Xiaoliang Wu, Wei Zhang, Ivy Shi, Rakesh K. Bagai, Patrick S. Leahy, Yan Feng, Martina L. Veigl, Daniel J. Lindner, David Danielpour et al. · 2016 · Oncotarget
  23. Genomic and Molecular Screenings Identify Different Mechanisms for Acquired Resistance to MET Inhibitors in Lung Cancer Cells
    Pol Giménez‐Xavier, Eva Pros, Ester Bonastre, Sebastián Morán, Ana Aza, Osvaldo Graña‐Castro, Gonzalo Goméz-López, Sophia V. Derdak, Marc Dabad, Anna Esteve‐Codina et al. · 2017 · Molecular Cancer Therapeutics
  24. Polyphyllin VII increases sensitivity to gefitinib by modulating the elevation of P21 in acquired gefitinib resistant non-small cell lung cancer
    Honggang Wang, Zhenghua Fei, Hao Jiang · 2017 · Journal of Pharmacological Sciences
  25. Combined effect of cabozantinib and gefitinib in crizotinib‐resistant lung tumors harboring ROS 1 fusions
    Yuka Kato, Kiichiro Ninomiya, Kadoaki Ohashi, Shuta Tomida, Go Makimoto, Hiromi Watanabe, Kenichiro Kudo, Shingo Matsumoto, Shigeki Umemura, Kōichi Goto et al. · 2018 · Cancer Science
  26. Cooperation and Interplay between EGFR Signalling and Extracellular Vesicle Biogenesis in Cancer
    Laura C. Zanetti-Domingues, Scott E. Bonner, R. Sumanth Iyer, Marisa L. Martin-Fernandez, Veronica Huber · 2020 · Cells
  27. First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?
    Shuyun Wang, Aiqin Gao, Jie Liu, Yuping Sun · 2018 · Cancer Chemotherapy and Pharmacology
  28. Phenotypic chemical screening using zebrafish neural crest reporters identifies retinoid acid as an inhibitor of epithelial morphogenesis
    Laura Jiménez, Jindong Wang, Monique A. Morrison, Clifford J. Whatcott, Katherine K. Soh, Steven L. Warner, David J. Bearss, Cicely A. Jette, Rodney A. Stewart · 2016 · Disease Models & Mechanisms
  29. Advances in Circulating Tumor DNA Analysis
    Samantha O. Perakis, Martina Auer, Jelena Belic, Ellen Heitzer · 2017 · Advances in clinical chemistry
  30. The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
    Elisa Zanini, Louay S. Louis, Jane Antony, Evdoxia Karali, Imoh Sunday Okon, Arthur B. McKie, Sebastian Vaughan, Mona A El-Bahrawy, Justin Stebbing, Chiara Recchi et al. · 2017 · Molecular Cancer Therapeutics
  31. Liquid biopsy uncovers distinct patterns of DNA methylation and copy number changes in NSCLC patients with different EGFR-TKI resistant mutations
    Hoai‐Nghia Nguyen, Ngoc-Phuong Thi Cao, Thien-Chi Van Nguyen, Khang Nguyen Duy Le, Dat Nguyen, Quynh‐Tho Thi Nguyen, Thai-Hoa Thi Nguyen, Chu Van Nguyen, Ha Thu Le, Trieu Vu Nguyen et al. · 2021 · Scientific Reports
  32. Pancreatic Cancer: Pathogenesis and Clinical Studies
    Kexun Zhou, Yingping Liu, Chuanyun Tang, Hong Zhu · 2025 · MedComm
  33. AUY922 Effectively Overcomes MET- and AXL-Mediated Resistance to EGFR-TKI in Lung Cancer Cells
    Yun Jung Choi, Seon Ye Kim, Kwang Sup So, In‐Jeoung Baek, Woo Sung Kim, Sehoon Choi, Jae Cheol Lee, Trever Grant Bivona, Jin Kyung Rho, Chang‐Min Choi · 2015 · PLoS ONE
  34. An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer
    Gayatri Premasekharan, Elizabeth Gilbert, Ross A. Okimoto, Ashiya Hamirani, Karla J. Lindquist, Vy Ngo, Ritu Roy, Jeffrey Hough, Matthew Edwards, Rosa Paz et al. · 2016 · Cancer Letters
  35. A novel human anti‐AXL monoclonal antibody attenuates tumour cell migration
    Yanting Duan, Longlong Luo, Chunxia Qiao, Xinying Li, Jing Wang, Hao Liu, Tingting Zhou, Beifen Shen, Ming Lv, Jiannan Feng · 2019 · Scandinavian Journal of Immunology
  36. Research progress on the relationship between lung cancer drug-resistance and microRNAs
    Xuan Ma, Ai-Ling Liang, Yongjun Liu · 2019 · Journal of Cancer
  37. Enhanced Sensitivity of Nonsmall Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor‐Tyrosine Kinase Inhibitors to Phenformin: The Roles of a Metabolic Shift to Oxidative Phosphorylation and Redox Balance
    Suntae Kim, Ji Hye Im, Wankyu Kim, Young Jae Choi, Ji Yoon Lee, Sang Kyum Kim, Sun Jo Kim, Sung Won Kwon, Keon Wook Kang · 2021 · Oxidative Medicine and Cellular Longevity
  38. STAT3 mediated upregulation of C-MET signaling acts as a compensatory survival mechanism upon EGFR family inhibition in chemoresistant breast cancer cells
    Yuying Zhu, He Zhang, Xingxing Han, Zhiyong Wang, Yanfen Cui, Ran Tian, Zhaosong Wang, Baoai Han, Jianfei Tian, Fei Zhang et al. · 2021 · Cancer Letters
  39. AXL antibody and AXL-ADC mediate antitumor efficacy via targeting AXL in tumor-intrinsic epithelial-mesenchymal transition and tumor-associated M2-like macrophage
    Jinpeng Pei, Yue Wang, Lanping Ma, Xin Wang, Liang Liu, Yu Zhang, Rui Jin, Zhiqiang Ren, Yan Deng, Jingkang Shen et al. · 2023 · Acta Pharmacologica Sinica
  40. Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond
    Christopher D. Delaney, Samuel Frank, R. Stephanie Huang · 2015 · 癌症：英文版
  41. A role for the pseudokinase HER3 in the acquired resistance against EGFR- and HER2-directed targeted therapy
    Jeroen Claus, Gargi Surendra Patel, Tony Ng, Peter J. Parker · 2014 · Biochemical Society Transactions
  42. Secrets of Drug Resistance in NSCLC Exposed by New Molecular Definition of EMT
    Dana S. Neel, Trever Grant Bivona · 2012 · Clinical Cancer Research
  43. Omega-3 Fatty Acid-Enriched Fish Oil and Selenium Combination Modulates Endoplasmic Reticulum Stress Response Elements and Reverses Acquired Gefitinib Resistance in HCC827 Lung Adenocarcinoma Cells
    Chien-Huang Liao, Yu-Tien Tzeng, Gi‐Ming Lai, Chia-Lun Chang, Ming-Hung Hu, Wei-Lun Tsai, Yun‐Ru Liu, Simon Hsia, Shuang‐En Chuang, Tzeon-Jye Chiou et al. · 2020 · Marine Drugs
  44. New apoptotic anti-triple-negative breast cancer theobromine derivative inhibiting EGFRWT and EGFRT790M: in silico and in vitro evaluation
    Ibrahim H. Eissa, Reda G. Yousef, Hazem Elkady, Aisha A. Alsfouk, Dalal Z. Husein, Ibrahim M. Ibrahim, Nehal M. El‐Deeb, Ahmed M. A. Kenawy, Wagdy Mohamed Eldehna, Eslam B. Elkaeed et al. · 2023 · Molecular Diversity
  45. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells
    Dario Presutti, Simonetta Santini, Beatrice Cardinali, Giuliana Papoff, Cristiana Lalli, Simone Samperna, Valentina Fustaino, Giuseppe Giannini, Giovina Ruberti · 2015 · PLoS ONE
  46. Electrochemical immunosensor for receptor tyrosine kinase AXL using poly(pyrrolepropionic acid)-modified disposable electrodes
    Verónica Serafín, Rebeca Magnolia Torrente-Rodríguez, M. Batlle, Pablo Garcı́a de Frutos, Susana Campuzano, Paloma Yáñez‐Sedeño, José Manuel Pingarrón · 2016 · Sensors and Actuators B Chemical
  47. Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients
    Lijun Dong, Dan Lei, Haijun Zhang · 2017 · Oncotarget
  48. Sensing of apoptotic cells through Axl causes lung basal cell proliferation in inflammatory diseases
    Naoya Fujino, Oliver J. Brand, David J. Morgan, Toshifumi Fujimori, Aleksander M. Grabiec, Christopher P. Jagger, Rose A. Maciewicz, Mitsuhiro Yamada, Koji Itakura, Hisatoshi Sugiura et al. · 2019 · The Journal of Experimental Medicine
  49. AXL, an Important Host Factor for DENV and ZIKV Replication
    Shengda Xie, Huiru Zhang, Zhenjie Liang, Xingmiao Yang, Ruibing Cao · 2021 · Frontiers in Cellular and Infection Microbiology
  50. AXL/CDCP1/SRC axis confers acquired resistance to osimertinib in lung cancer
    Yûichi Murakami, Daiki Kusakabe, Kosuke Watari, Akihiko Kawahara, Koichi Azuma, Jun Akiba, Masahiko Taniguchi, Michihiko Kuwano, Mayumi Ono · 2022 · Scientific Reports
  51. JNK Pathway Activation Modulates Acquired Resistance to EGFR/HER2–Targeted Therapies
    Simin Manole, Edward J. Richards, Aaron S. Meyer · 2016 · Cancer Research
  52. Deep-proteome mapping of WM-266-4 human metastatic melanoma cells: From oncogenic addiction to druggable targets
    Eumorphia G. Konstantakou, Athanassios D. Velentzas, Athanasios K. Anagnostopoulos, Zoi I. Litou, Ourania A. Konstandi, Aikaterini F. Giannopoulou, Ema Anastasiadou, Gerassimos E. Voutsinas, George Th. Tsangaris, Dimitrios J. Stravopodis · 2017 · PLoS ONE
  53. A Vesicular Stomatitis Virus‐Inspired DNA Nanocomplex for Ovarian Cancer Therapy
    Wei Zhao, Yuping Yang, Lingling Song, Tianyi Kang, Ting Du, Yujiao Wu, Meimei Xiong, Li Luo, Jianlin Long, Ke Men et al. · 2017 · Advanced Science
  54. Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
    Jae Cheol Lee, Seung Hun Jang, Kye Young Lee, Young‐Chul Kim · 2013 · Cancer Research and Treatment
  55. Novel molecular targets for the treatment of lung cancer
    Rafael Rosell, Niki Karachaliou, Oscar G. Arrieta · 2019 · Current Opinion in Oncology
  56. Regulation of the Receptor Tyrosine Kinase AXL in Response to Therapy and Its Role in Therapy Resistance in Glioblastoma
    Lea Scherschinski, Markus Prem, Irina Kremenetskaia, Ingeborg Tinhofer, Peter Vajkoczy, Anna-Gila Karbe, Julia Onken · 2022 · International Journal of Molecular Sciences
  57. Research Progress on Therapeutic Targeting of Cancer-Associated Fibroblasts to Tackle Treatment-Resistant NSCLC
    Chenxin Li, Yusong Qiu, Yong Zhang · 2022 · Pharmaceuticals
  58. AXL – a new player in resistance to HER2 blockade
    Anna Adam‐Artigues, Enrique Javier Arenas, Joaquín Arribas, Aleix Prat, Juan Miguel Cejalvo · 2023 · Cancer Treatment Reviews
  59. Gas6/Axl is the sensor of arginine-auxotrophic response in targeted chemotherapy with arginine-depleting agents
    W-B Tsai, Y Long, J-R Park, Jeffrey T. Chang, Hui Liu, Jaime Rodriguez‐Canales, Niramol Savaraj, Lynn G. Feun, Michael A. Davies, Ignacio Ivan Wistuba et al. · 2015 · Oncogene
  60. Prediction of signaling cross-talks contributing to acquired drug resistance in breast cancer cells by Bayesian statistical modeling
    AKM Azad, Alfons Lawen, Jonathan Macgregor Keith · 2015 · BMC Systems Biology
  61. Insights into the roles of hnRNP A2/B1 and AXL in non-small cell lung cancer
    Xiaohan Qu, Jinlu Liu, Xinwen Zhong, Xi Li, Qigang Zhang · 2015 · Oncology Letters
  62. Upregulation of Bcl2 in NSCLC with acquired resistance to EGFR‑TKI
    Hio Teng Cheong, Fei Xu, Chi Tung Choy, Connie Wun Chun Hui, Tony S.K. Mok, Chi Hang Wong · 2017 · Oncology Letters
  63. Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–small-cell Lung Carcinoma
    Beth A. Hellerstedt, Nicholas J. Vogelzang, Harriet M. Kluger, Christopher A. Yasenchak, Dana T. Aftab, David Albert Ramies, Michael S. Gordon, Primo N. Lara · 2018 · Clinical Lung Cancer
  64. Adrenergic Blockade Promotes Maintenance of Dormancy in Prostate Cancer Through Upregulation of GAS6
    Ann M. Decker, Joseph T. Decker, Younghun Jung, Frank Cameron Cackowski, Stephanie Daignault‐Newton, Todd Matthew Morgan, Lonnie D. Shea, Russell S. Taichman · 2020 · Translational Oncology
  65. Identification of novel bioactive molecules from garlic bulbs: A special effort to determine the anticancer potential against lung cancer with targeted drugs
    RAMAKRISHNAN PADMINI, V. Uma Maheshwari, Parameswaran Saravanan, Keun Woo Lee, M. Razia, Mona S. Alwahibi, Balasubramani Ravindran, Mohamed Soliman Elshikh, Young Ock Kim, Hyungsuk Kim et al. · 2020 · Saudi Journal of Biological Sciences
  66. Efficacy of the CDK7 Inhibitor on EMT-Associated Resistance to 3rd Generation EGFR-TKIs in Non-Small Cell Lung Cancer Cell Lines
    Wonjun Ji, Yun Jung Choi, Myoung Hee Kang, Ki Jung Sung, Dong Ha Kim, Sangyong Jung, Chang‐Min Choi, Jae Cheol Lee, Jin Kyung Rho · 2020 · Cells
  67. Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer
    Joan Rou-En Choo, Chee‐Seng Tan, Ross Andrew Soo · 2018 · Targeted Oncology
  68. Overcoming Resistance to AC0010, a Third Generation of EGFR Inhibitor, by Targeting c-MET and BCL-2
    Xu, Wanhong, Tang, Wei, Li, Tingting, Zhang, Xiaoying, Sun, Yi · 2019 · Neoplasia
  69. Single cell lineage tracing reveals clonal dynamics of anti-EGFR therapy resistance in triple negative breast cancer
    Simona Pellecchia, Melania Franchini, Gaetano Viscido, Riccardo Arnese, Gennaro Gambardella · 2024 · Genome Medicine
  70. MET: A New Promising Biomarker in Non-Small-Cell Lung Carcinoma
    Cristina Pérez-Ramírez, Marisa Cañadas‐Garre, Enrique Jiménez‐Varo, María José Faus-Dáder, Miguel Ángel Calleja‐Hernández · 2015 · Pharmacogenomics
  71. MiR-30 Family Potentially Targeting PI3K-SIAH2 Predicted Interaction Network Represents a Novel Putative Theranostic Panel in Non-small Cell Lung Cancer
    Lawrence Chan, Fengfeng Wang, Fei Meng, Lili Wang, Sze Chuen Cesar Wong, Joseph S. K. Au, Sijun Yang, William C. S. Cho · 2017 · Frontiers in Genetics
  72. Management of Egfr-Mutated Non-Small-Cell Lung Cancer: Practical Implications from a Clinical and Pathology Perspective
    Michael Cabanero, Randeep S. Sangha, Brandon S. Sheffield, Mahadeo A. Sukhai, Mini Pakkal, Suzanne Kamel‐Reid, Aly Karsan, Diana N. Ionescu, Rosalyn Anne Juergens, Charles Andrew Butts et al. · 2017 · Current Oncology
  73. High expression of NEK2 promotes lung cancer progression and drug resistance and is regulated by mutant EGFR
    Chuanhui Chen, Shanshan Peng, Penghui Li, Lin Ma, Xin Gan · 2020 · Molecular and Cellular Biochemistry
  74. Integrated Omics Analysis of Non-Small-Cell Lung Cancer Cells Harboring the EGFR C797S Mutation Reveals the Potential of AXL as a Novel Therapeutic Target in TKI-Resistant Lung Cancer
    Tong‐Hong Wang, Chih‐Ching Wu, Kuo‐Yen Huang, Yann‐Lii Leu, Shuenn‐Chen Yang, Ci‐Ling Chen, Chi‐Yuan Chen · 2020 · Cancers
  75. Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models
    Ilaria Marrocco, Donatella Romaniello, Itay Vaknin, Diana Drago Garcia, Roni Oren, Mary Luz Uribe, Nishanth Belugali Nataraj, Soma Ghosh, Raya Eilam, Tomer‐Meir Salame et al. · 2021 · EMBO Molecular Medicine
  76. Therapeutic Targeting of the Anaplastic Lymphoma Kinase (ALK) in Neuroblastoma—A Comprehensive Update
    Annette K. Brenner, Maria Winther Gunnes · 2021 · Pharmaceutics
  77. Current therapy and development of therapeutic agents for lung cancer
    Zilai Wang, Jiyeon Kim, Pin Zhang, Jazmin Galván Achi, Yuwei Jiang, Lijun Rong · 2022 · Cell Insight
  78. Utilising the EGFR interactome to identify mechanisms of drug resistance in non-small cell lung cancer – Proof of concept towards a systems pharmacology approach
    Hisham Saafan, Sarah Foerster, Zinnia Patricia Parra-Guillen, Elke Hammer, Martin Michaelis, Jindrich Jr. Cinatl, Uwe Völker, Holger Fröhlich, Charlotte Kloft, Christoph Alexander Ritter · 2016 · European Journal of Pharmaceutical Sciences
  79. Marsdenia tenacissima extract overcomes Axl- and Met-mediated erlotinib and gefitinib cross-resistance in non-small cell lung cancer cells
    Shu-Yan Han, Wei Zhao, Hai-Bo Han, Hong Sun, Dong Xue, Yan-Na Jiao, Xi-Ran He, Shan-Tong Jiang, Pingping Li · 2017 · Oncotarget
  80. Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer
    Nele Van Der Steen, Elisa Giovannetti, Daniela Carbone, Alessandro Leonetti, Christian Diego Rolfo, Godefridus J. Peters · 2018 · Cancer Drug Resistance
  81. Applications of liquid biopsy in lung cancer-diagnosis, prognosis prediction, and disease monitoring.
    Wenna Luo, Mingliang Rao, Jiayao Qu, Dixian Luo · 2018 · Europe PMC (PubMed Central)
  82. Axl receptor tyrosine kinase is a novel target of apigenin for the inhibition of cell proliferation
    KYUNG-CHAN KIM, Eun Ha Choi, ChuHee Lee · 2014 · International Journal of Molecular Medicine
  83. AXL/WRNIP1 Mediates Replication Stress Response and Promotes Therapy Resistance and Metachronous Metastasis in HER2+ Breast Cancer
    Mauricio Marquez-Palencia, Luis Reza Herrera, Pravat Kumar Parida, Suvranil Ghosh, Kangsan Kim, Nikitha M. Das, Paula I. González Ericsson, Melinda E. Sanders, Bret C. Mobley, Sebastian Diegeler et al. · 2024 · Cancer Research
  84. Multiplexed Analysis for Anti-Epidermal Growth Factor Receptor Tumor Cell Growth Inhibition Based on Quantum Dot Probes
    Dahai Ren, Yiqiu Xia, Bin Wang, Zheng You · 2016 · Analytical Chemistry
  85. Guidance of Signaling Activations by Cadherins and Integrins in Epithelial Ovarian Cancer Cells
    Francesca Roggiani, Delia Mezzanzanica, Katia Rea, Antonella Tomassetti · 2016 · International Journal of Molecular Sciences
  86. Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer
    Corallo, Salvatore, D’Argento, Ettore, Strippoli, Antonia, Basso, Michele, Monterisi, Santa, Rossi, Sabrina, Cassano, Alessandra, Barone, Carlo M. · 2017 · Targeted Oncology
  87. Targeting AXL in NSCLC
    Aubhishek Zaman, Trever Grant Bivona · 2021 · Lung Cancer Targets and Therapy
  88. Targeting Oncogenic KRAS in Non-Small-Cell Lung Cancer
    Noriaki Sunaga, Yosuke Miura, Norimitsu Kasahara, Reiko Sakurai · 2021 · Cancers
  89. Heterogeneity of glutamine metabolism in acquired-EGFR-TKI-resistant lung cancer
    Suntae Kim, Jang Su Jeon, Yong June Choi, Ga Hee Baek, Sang Kyum Kim, Keon Wook Kang · 2022 · Life Sciences
  90. High levels of AXL expression in untreated EGFR ‐mutated non‐small cell lung cancer negatively impacts the use of osimertinib
    Akihiro Yoshimura, Tadaaki Yamada, Masakuni Serizawa, Hisanori Uehara, Keiko Tanimura, Yusuke Okuma, Akito Fukuda, Satoshi Watanabe, Naoya Nishioka, Takayuki Takeda et al. · 2022 · Cancer Science
  91. Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC
    Keigo Kobayashi, Aaron C. Tan · 2023 · International Journal of Molecular Sciences
  92. Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer
    Jakob Schöttle, Sampurna Chatterjee, Caroline Volz, Maike Siobal, Alexandra Florin, Dennis Rokitta, Yvonne Hinze, Felix Dietlein, Dennis Plenker, Katharina König et al. · 2015 · Oncotarget
  93. NF-κB activation is an early event of changes in gene regulation for acquiring drug resistance in human adenocarcinoma PC-9 cells
    Masashi Fukuoka, Katsuji Yoshioka, Hirohiko Hohjoh · 2018 · PLoS ONE
  94. Ion Channels in Lung Cancer
    Etmar Bulk, Luca Matteo Todesca, Albrecht Schwab · 2020 · Reviews of physiology, biochemistry and pharmacology
  95. Axl inhibition: a potential road to a novel acute myeloid leukemia therapy?
    Melanie Janning, Isabel Ben Batalla, Sonja Loges · 2015 · Expert Review of Hematology
  96. Advances in Lung Cancer Basic and Translational Research in 2025 – Overview and Perspectives Focusing on NSCLC
    Céline Mascaux, Triparna Sen, Montse Sánchez‐Céspedes, Sandra Ortiz‐Cuaran, Yohan Bossé, Floris F. Dammeijer, Milena R. Cavic, Martin P. Barr, Surein Arulananda, Ricardo Armisén et al. · 2025 · Journal of Thoracic Oncology
  97. Coexpression of receptor tyrosine kinase AXL and EGFR in human primary lung adenocarcinomas
    Zhenzhou Wu, Fan Bai, Liyun Fan, Wenshuai Pang, Ruiyu Han, Juan Wang, Yueping Liu, Yan Xia, Huijun Duan, Lingxiao Xing · 2015 · Human Pathology
  98. Synthesis and antiproliferative activity of pyrrolo[2,3-b]pyridine derivatives bearing the 1,8-naphthyridin-2-one moiety
    Qidong Tang, Yongli Duan, Linxiao Wang, Min Wang, Yiqiang Ouyang, Caolin Wang, Mei Han, Sheng Tang, Yinhua Xiong, Pengwu Zheng et al. · 2017 · European Journal of Medicinal Chemistry
  99. Intrinsic Differences in Spatiotemporal Organization and Stromal Cell Interactions Between Isogenic Lung Cancer Cells of Epithelial and Mesenchymal Phenotypes Revealed by High-Dimensional Single-Cell Analysis of Heterotypic 3D Spheroid Models
    Maria Lie Lotsberg, Gro Vatne Røsland, Austin J. Rayford, Sissel E. Dyrstad, Camilla Tvedt Ekanger, Ning Lü, Kirstine Frantz, Linda E. B. Stuhr, Henrik J. Ditzel, Jean Paul Thiery et al. · 2022 · Frontiers in Oncology
  100. AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer
    Mari Iida, Nellie K. McDaniel, Kourtney L. Kostecki, Noah B. Welke, Carlene A. Kranjac, Peng Liu, Colin A. Longhurst, Justine Y. Bruce, Seungpyo Hong, Ravi Salgia et al. · 2022 · BMC Cancer